SOURCE: Actinium Pharmaceuticals
Felix Garzon MD, PH.D.: Record of Success Strengthens Team as Company Prepares for the Iomab-B Pivotal Trial
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM)
("Actinium" or "the Company"), a biopharmaceutical Company developing
innovative targeted payload immunotherapeutics for the treatment of
advanced cancers, announced today the appointment of Felix Garzon, MD,
Ph.D. to the position of Senior Vice President, Head of Clinical
Development effective August 17, 2015. Dr. Garzon brings with him 28
years of pertinent pharmaceutical and biotechnology experience in
increasingly senior roles, most recently at Eisai and Bristol-Myers
Squibb, having worked on both later and earlier stages of drug
development.
"Felix's deep expertise in hematology and oncology
drug development will strengthen the Actinium team in an important way.
He brings to Actinium a rigorous track record of successful clinical
development in diverse settings including leadership roles with
international product teams in large and small companies and in
different therapeutic indications," said Kaushik J. Dave, Ph.D., Chief
Executive Officer of Actinium Pharmaceuticals. "In addition, Felix has
significant clinical trial management and regulatory experience. All of
these are key skills as we ramp up our preparations for the upcoming
trials for Iomab-B and Actimab-A."
Dragan Cicic, MD, Chief Medical
Officer of Actinium added, "Felix is a great addition to our team,
whose vast experience in and focus on hematologic oncology will enable
us to execute our ambitious programs in a timely and precise manner."
"I
am very excited to join the Actinium organization," said Dr. Garzon.
"Actinium is pursuing breakthroughs in the field in which I have more
than a quarter of a century of professional experience. With two very
promising products poised to enter Phase 3 and Phase 2 trials, I am
thrilled to have an opportunity to maximize the development prospects
for Iomab-B and Actimab-A. As we build and strengthen the clinical team
to meet milestones, I look forward to adding value by generating high
quality clinical data to help achieve timeline objectives."
Dr.
Garzon has more than 28 years of robust international experience working
in positions of increasing responsibility in the development of new
oncology and hematology drugs in several successful companies in the
United States and Europe. He has successfully led and managed the late
development and approval of several anticancer drugs, including
Halaven®, Trisenox® and Xyotax®. Other roles included Clinical Lead at a
Product Creation Unit, Head of Medical Affairs and strategic
development plan creation and implementation. Prior to his extensive
work in oncology drug development for the pharmaceutical industry, he
worked as a scientist in the research of new anti-cancer drugs for
several years at the Institute of Toxicology & Chemotherapy of the
German Cancer Research Centre, Heidelberg, Germany. Dr. Garzon is the
author and co-author of over 80 relevant scientific publications,
abstracts and presentations given at international scientific meetings.
Dr.
Garzon was previously Senior Director, Oncology Product Creation Unit
at Eisai, and Director, Oncology Global Clinical Research at
Bristol-Myers Squibb. He also had roles at Chiron, Cell Therapeutics,
Rhône-Poulenc Rorer, Pharmacia & Upjohn and Ipsen, following
academic appointments and education in Germany, France and Argentina.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com)
is a New York-based biopharmaceutical company developing innovative
targeted payload immunotherapeutics for the treatment of advanced
cancers. Actinium's targeted radiotherapy products are based on its
proprietary delivery platform for the therapeutic utilization of
alpha-emitting actinium-225 and bismuth-213 and certain beta emitting
radiopharmaceuticals in conjunction with monoclonal antibodies. The
Company's lead radiopharmaceutical product candidate Iomab-B is designed
to be used, upon approval, in preparing patients for hematopoietic stem
cell transplant, commonly referred to as bone marrow transplant. The
Company plans to conduct a single, pivotal, multicenter Phase 3 clinical
study of Iomab-B in refractory and relapsed AML patients over the age
of 55 with a primary endpoint of durable complete remission. The
Company's second product candidate, Actimab-A, is continuing its
clinical development in a Phase 1/2 trial for newly diagnosed AML
patients over the age of 60 in a single-arm multicenter trial.
No comments:
Post a Comment